For 2025, many traders project "CABA stock forecast" levels supported by historical volume spikes and biotech ETF performance. If the industry maintains its 12% CAGR, market consensus suggests price resistance near $23, assuming no major delays in product commercialization. Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. CABA stock is trading at around $1.87 per share now. The analysts' average price target of $24.70 implies the stock has an upside potential of more than 1,183% over the next 12 months. Investors tracking the "CABA stock forecast 2025" see strong upside potential if the company secures regulatory approvals for its gene therapy pipeline. Institutional buying patterns since Q1 2024 have indicated growing confidence, with projected revenue increases aligning with sector-wide biotech growth rates.
